依伏卡塞衍生物对糖尿病性骨质疏松的改善和促成骨作用
陈美轩 , 刘凯 , 徐源 , 华圆 , 郭怡洵 , 张恺 , 张岩
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1193 -1199.
依伏卡塞衍生物对糖尿病性骨质疏松的改善和促成骨作用
Evocalcet derivative attenuates diabetic osteoporosis and promotes osteogenesis
目的: 评估钙敏感受体(CaSR)激动剂依伏卡塞衍生物对糖尿病小鼠骨质疏松的改善作用及其促成骨作用。方法: C57BL/6 小鼠随机分为正常对照组、模型组、依伏卡塞衍生物组。采用高脂饮食结合腹腔低剂量注射链脲佐菌素(30 mg/kg)的方法,建立 2 型糖尿病(T2DM)小鼠模型。治疗组每天灌胃给予以 0.5%CMC-Na 为溶剂的依伏卡塞衍生物(0.6 mg/kg),其余组给予等量 0.5%CMC-Na 溶液,连续 6 周,给药期间以 2 周为间隔动态监测小鼠体质量和空腹血糖。检测各组小鼠血清钙(Ca)、磷(Pi)含量,采用微焦点定量 CT(Micro-CT)检测小鼠骨密度和骨微结构,通过三点弯曲生物力学检测小鼠股骨中段力学参数,使用 HE 染色、ALP 染色检测骨组织形态学与成骨细胞 , 并通过 Western blot 检测 CaSR 下游分子及成骨相关分子的蛋白表达。结果: 依伏卡塞衍生物干预后,小鼠血清中 Ca、Pi 含量明显降低(P<0.05);Micro-CT 检测分析显示,小鼠胫骨近端骨密度明显增加(P<0.05),骨小梁间隙明显减小(P<0.001),骨小梁厚度明显增加(P<0.05),并且,骨小梁面积百分比明显增加(P<0.05);生物力学测试表明,小鼠股骨中段的最大载荷、最大变形和弹性变形都显著增加(P<0.05);相对于模型组,给药组的成骨细胞数量显著增加(P<0.01);Western blot 结果显示,依伏卡塞衍生物显著升高 T2DM 小鼠骨组织 p-ERK/ERK 表达比值 (P<0.001), 上调 Runx2 和 COL-Ⅰ的蛋白表达(P<0.05)。结论: 新一代拟钙剂依伏卡塞衍生物通过直接作用于骨骼 CaSR,进而激活其下游 ERK/Runx2/COL-Ⅰ信号通路,发挥促成骨作用,改善糖尿病性骨质疏松。
AIM: To evaluate the ameliorative effect of calcium-sensing receptor (CaSR) agonist evocalcet derivative on osteoporosis in diabetic mice and its stimulative effect on osteogenesis. METHODS: The C57BL/6 mice were randomly divided into a normal control group, a model group, and an evocalcet derivative group. A type 2 diabetes mellitus (T2DM) mouse model was established by a high-fat diet combined with intraperitoneal injection of low-dose streptozotocin (30 mg/kg). The mice in the treatment group were daily administered with an evocalcet derivative (0.6 mg/kg, i.g.) in 0.5% CMC-Na solution, while the mice in other groups were administered with an equal volume of 0.5% CMC-Na solution for 6 weeks. During the administration period, the body weight and the fasting blood glucose levels of the mice were dynamically monitored at 2-week intervals. Serum calcium (Ca) and phosphorus (Pi) levels were measured in each group. Micro-CT was used to detect bone mineral density and bone microstructure, and a three-point bending biomechanics test was performed to detect the mechanical parameters at the mid-shaft of the mice femur. HE staining and ALP staining were respectively used to detect bone histomorphology and osteoblasts, and Western blot was carried out to measure the protein expression of CaSR downstream molecules and osteogenic-related molecules. RESULTS: After intervention with an evocalcet derivative, serum Ca and Pi levels in mice were significantly reduced (P<0.05). Micro-CT showed a significant increase in bone mineral density (P<0.05) and in trabecular thickness (P<0.05), and a significant decrease in trabecular bone separation (P<0.001); moreover, the area percentage of trabecular bone was dramatically enhanced (P<0.05) at the proximal end of the mice tibia. Biomechanical tests showed a significant elevation in maximum load, maximum deformation, and elastic deformation (P<0.05) at the diaphysis of the mice femur. As compared to the model group, the drug treatment induced a significant increase (P<0.01) in the number of osteoblasts. The Western blot results showed that the evocalcet derivative elevated the expression ratio of p-ERK/ERK (P<0.001) and upregulated protein expression (P<0.05) of Runx2 and COL-Ⅰ in the bone tissue of T2DM mice. CONCLUSION: The new generation calcimimetic agent evocalcet derivative could directly act on CaSR in bone, followed by stimulating its downstream ERK/Runx2/COL-Ⅰ signaling pathway, thereby improving diabetic osteoporosis by exerting its osteogenic effect.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
左力, 甘良英. 拟钙剂治疗维持性血液透析患者继发性甲状旁腺功能亢进症的中国专家共识 (2024 版)[J].中国血液净化, 2024, 23(10): 721-735. |
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
International Osteoporosis Foundation. Facts and statistics[EB/OL]. (2024)[2026-08-21].https://www.osteoporosis.foundation/facts-statistics[reference:3][reference:4]. |
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
河北省创新能力提升计划项目--高水平人才团队建设专项(244A7615D)
河北省慢性肾病治疗药物开发重点实验室(SZQ202506)
河北省高等学校科学研究产学研合作项目(CXZX2025017)
上海中医药大学附属龙华医院“龙医学者”临床科技创新计划(KC2026009)
科技创新基础研究项目(CX202512)
/
| 〈 |
|
〉 |